Proacta Incorporated

The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer. The company says that developme

Following a setback earlier this year, the privately held Japanese bioventure LivTech has bounced back with a new deal for one of its main streams of research, signing an option agreement with Yakult

In Vitro Diagnostics Mergers & Acquisitions /In Vitro Diagnostics Astellas Pharma Inc. Cell Signaling Technology Inc. Pfizer Inc. Cell Signaling Technology Inc. (CST; research tools for identifyin

Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer. Yakult acquired e